Skip To Main Content
Staphylococcus aureus on Muck Rack

Staphylococcus aureus

As seen in: Genetic Engineering & Biotechnology News, RXLIST®, WhaTech
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Staphylococcus

Contact Staphylococcus, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Innovations In Tracheitis Treatment With Wockhardt s Novel Antibiotic: Key Trend in The Tracheitis Treatment Global Market 2025-2034

|
By Oliver Guirdham, Staphylococcus aureus, Other End-Users
| WhaTech
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today! What Are The Latest Market Size Figures And Growth Trends For The Tracheitis Treatment Market? In the past few years, there has been a consistent expansion in the tracheitis treatment market. The market worth was estimated to be $5.79 billion in 2024 and is projected to increase to $5.96 billion in 2025, boasting a compound annual growth rate (CAGR) of 3.0%.
Open in Who Shared Issue with article?

Current trends in the determination of microbiological indicators of dairy products - Journal of Food Science and Technology

|
By Staphylococcus aureus
| link.springer.com
Abstract Milk and dairy products are the most common and widely consumed foods. At the same time, milk is often contaminated with pathogenic microorganisms by endo- and exogenous ways, which can cause various defects in raw materials and finished products. Recently, new techniques have been developed for monitoring microbiological indicators of milk, which are characterized by simplicity, ease of use and high reliability.
Open in Who Shared Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Staphylococcus aureus, T. Holland, S. Cosgrove, Biomedical Advanced
| Sparda-Bank web.Börsenforum
* Clinical portfolio substantially strengthened through business development in 2023; two phase 3 studies expected to start in 2024 * Cresemba in-market sales of USD 445 million, increased 22% year-on-year, in 12-month period ending September 2023; 6-months market exclusivity extension granted in the US * FDA PDUFA target action date on ceftobiprole US NDA April 3; US commercialization partner expected to be announced prior to FDA decision Allschwil, Switzerland, January 5, 2024 Basilea...
Open in Who Shared View Duplicates (159) Issue with article?
See all 8 articles